Phase III Study of Pemetrexed in Combination With Cisplatin Versus Cisplatin Alone in Patients With Malignant Pleural Mesothelioma

MLA

Ulrich Gatzemeier, et al. “Phase III Study of Pemetrexed in Combination With Cisplatin Versus Cisplatin Alone in Patients With Malignant Pleural Mesothelioma.” Journal of Clinical Oncology, vol. 41, Apr. 2023, pp. 2125–33. EBSCOhost, https://doi.org/10.1200/jco.22.02542.

APA

Ulrich Gatzemeier, Michael Boyer, Paolo Paoletti, Salih Emri, Christian Manegold, Claude Denham, Nicholas J. Vogelzang, James J. Rusthoven, James T. Symanowski, Clet Niyikiza, E. Kaukel, & Pierre Ruffié. (2023). Phase III Study of Pemetrexed in Combination With Cisplatin Versus Cisplatin Alone in Patients With Malignant Pleural Mesothelioma. Journal of Clinical Oncology, 41, 2125–2133. https://doi.org/10.1200/jco.22.02542

Chicago

Ulrich Gatzemeier, Michael Boyer, Paolo Paoletti, Salih Emri, Christian Manegold, Claude Denham, Nicholas J. Vogelzang, et al. 2023. “Phase III Study of Pemetrexed in Combination With Cisplatin Versus Cisplatin Alone in Patients With Malignant Pleural Mesothelioma.” Journal of Clinical Oncology 41 (April): 2125–33. doi:10.1200/jco.22.02542.